Mechanism of Action of Troculeucel (Non‐genetically Modified Natural Killer Cells with Enhanced Cytotoxicity) in Alzheimer's Disease Confirmed by Corresponding Phase I Biomarker Data.
Troculeucel is consistently produced from AD patients and can cross the blood-brain barrier via CXCR3 to improve CSF levels of amyloid and alpha-synuclein proteins, while targeting autoreactive T cells to reduce neuroinflammation. Reduction of GFAP appears to be correlated with stabilization or improvement in ADCOMS scores observed in the study.
Authors
- Lucia Hui
- Paul Y. Song (ORCID: https://orcid.org/0009-0004-3270-0324)
- Katia Betito (ORCID: https://orcid.org/0000-0002-9489-2649)
- Yoonmi Kang
- Rufino Menchaca Díaz
- Sean Hong (ORCID: https://orcid.org/0009-0003-9373-263X)
- Cesar Alejandro Amescua
- Blanca Isaura Acosta Gallo
- Hank Lee
- Harry Chung
- Clemente Humberto Zúñiga Gil
- Minchan Gil
- Jesse Carr
- Juan Mata
- Yongman Kim
Institutions
- Universidad de Tijuana (MX)
- Dermatology Specialists (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_101711
- Primary Topic
- Neuroinflammation and Neurodegeneration Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00